Akums Drugs and Pharmaceuticals Limited

rs,

bai – 400 051 To, The Listing Department BSE Limited Rotunda Building, Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai – 400 001 Symbol: AKUMS Scrip Code: 544222 Sub: Disclosure under R

INR 1,518

art consideration for the EU contract in this quarter, consequently our cash surplus now stands at INR 1,518 cr. The strong liquidity position provides a robust foundation for Akums to strategically scale up

0.5%

s. The first quarter of FY26 continued to see tepid volume growth, with market volume growth below 0.5% and IPM growth being driven largely by price growth. The weakness in API pricing continues. Lookin

14.8%

e Highlights 8 Consolidated Performance Highlights Q1 FY26 Segment Break-up 1,051 cr 156 cr 14.8% 65 cr 6.2% Total Income (+2.4% YoY) Adj. EBITDA (+208 bps YoY) Adj. PAT (+57 bps YoY) Bus

6.2%

8 Consolidated Performance Highlights Q1 FY26 Segment Break-up 1,051 cr 156 cr 14.8% 65 cr 6.2% Total Income (+2.4% YoY) Adj. EBITDA (+208 bps YoY) Adj. PAT (+57 bps YoY) Business Vertica

2.4%

rmance Highlights Q1 FY26 Segment Break-up 1,051 cr 156 cr 14.8% 65 cr 6.2% Total Income (+2.4% YoY) Adj. EBITDA (+208 bps YoY) Adj. PAT (+57 bps YoY) Business Vertical CDMO Domestic Bran

208 bps

Segment Break-up 1,051 cr 156 cr 14.8% 65 cr 6.2% Total Income (+2.4% YoY) Adj. EBITDA (+208 bps YoY) Adj. PAT (+57 bps YoY) Business Vertical CDMO Domestic Branded Formulation API Intern

57 bps

cr 156 cr 14.8% 65 cr 6.2% Total Income (+2.4% YoY) Adj. EBITDA (+208 bps YoY) Adj. PAT (+57 bps YoY) Business Vertical CDMO Domestic Branded Formulation API International Branded Formulat

79.4%

d Formulation API International Branded Formulation Trade Generics Share in Q1 FY26 revenue 79.4% 10.5% 4.4% 3.4% 2.3% (Adjusted EBITDA = Profit before tax + fair value changes to financial in

10.5%

ulation API International Branded Formulation Trade Generics Share in Q1 FY26 revenue 79.4% 10.5% 4.4% 3.4% 2.3% (Adjusted EBITDA = Profit before tax + fair value changes to financial instrumen

4.4%

API International Branded Formulation Trade Generics Share in Q1 FY26 revenue 79.4% 10.5% 4.4% 3.4% 2.3% (Adjusted EBITDA = Profit before tax + fair value changes to financial instrument + fi

3.4%

International Branded Formulation Trade Generics Share in Q1 FY26 revenue 79.4% 10.5% 4.4% 3.4% 2.3% (Adjusted EBITDA = Profit before tax + fair value changes to financial instrument + finance